6.260USD-1.11%Mkt Cap: —P/E: —1d ago
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company produ…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value831.76M $
Revenue (TTM)8.22M $
Gross Profit-62.27M $
Net Income (TTM)-75.74M $
Revenue/Share0.0640 USD
Last Price6.260 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees69
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-9.72
EV/Revenue101.20
P/S—
P/B7.00
EPS (TTM)-1.36
EPS (Forward)—
52W Range
5.88767% of range6.440
52W High6.440 USD
52W Low5.887 USD
Profitability
Gross Margin0.00%
Oper. Margin-1469.49%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-59.10%
ROA-28.98%
Growth
Revenue Growth-8.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-62.06M $
CapEx (TTM)—
FCF Margin-510.65%
FCF Yield—
Net Debt-89.71M $
Net Debt/EBITDA1.05
Balance Sheet
Debt/Equity1.49
Current Ratio3.46
Quick Ratio3.46
Book Value/Sh0.8910 USD
Cash/Share0.6220 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.40.94M
Float109.90M
Insiders2.18%
Institutions81.39%
Technical
SMA 501.202 (+420.6%)
SMA 2004.306 (+45.4%)
Beta0.78
S&P 52W Chg18.16%
Avg Vol (30d)1.58K
Avg Vol (10d)14.01K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—